ZYBERNO
Stock Report
Updated Jun 8, 2026

TC BIOPHARM (HOLDINGS) PLC (TCBPY)

Healthcare • Over The Counter

$0.01

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
TC BIOPHARM (HOLDINGS) PLC (TCBPY) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-348.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

TC BIOPHARM (HOLDINGS) PLC (TCBPY) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.01
Market Cap:$593.42K

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$5.88M
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-2.0%
Fundamental Growth Rate (g):7.0%

Margin Analysis (1)

Ebitda Margin:-413.2%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.81x
Quick Ratio:0.81x
Cash Ratio:0.52x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.27x
Times Interest Earned:-2.27

Capital Structure (4)

Working Capital:-2,309,912.96
Cash And Cash Equivalents:6,470,783.31
Long Term Debt:$0.00
Net Debt:-$6.47M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$5.17M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$21.38M

Bottom Line Performance (3)

-$1.87M
Income Before Tax:$0.00
Ebitda Ttm:-21,380,536.31

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$2.31M
Interest Expense:9,413,234.36

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-413.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.08M
Current Assets:$10.02M
Ppe Net:2,370,219.16
Goodwill:0.00
Intangible Assets:$744.26K

Liability Structure (4)

Total Liabilities:11,109,858.49
Current Liabilities:12,332,928.94
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$34.56K
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:1,237,422.27
Inventory:0.00
Accounts Payable:1,187,503.12

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.55M-$19.88M

Investment Activities (1)

Investing Cash Flow:-$417.47K

Financing Activities (3)

Financing Cash Flow:$24.08M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$0.20

Book Value & Capital (2)

Book Value Per Share:-$0.00
Cash Per Share:0.07

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.47x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:4.18x
Days Sales Outstanding Ttm:87.29

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:83.77
Cash Conversion Cycle:-995.48
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.0%
Fundamental Growth Rate (g):7.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:TCBPY
Company Name:TC BIOPHARM (HOLDINGS) PLC
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:98.90M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 22:59:13 UTC
Data Timestamp:2026-06-08T22:59:13.935283
Scroll to Top